Building a safer CAR-T therapy
FEBRUARY 3, 2020, NEW YORK — A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell–a family of promising immunotherapies for cancer–that can be switched on and off on demand. The study, led by Melita Irving of the Lausanne Branch of the Ludwig Institute for Cancer Research, George Coukos,…